title: Bevacizumab for glioblastoma: what can we learn from patterns of progression?
authors.affiliation: From the Center for Neuro-Oncology (P.Y.W.), Dana Farber/Brigham and Women's Cancer Center, and Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital, Boston, MA; and the Department of Neurology and Comprehensive Cancer Center (L.J.), University of Michigan, Ann Arbor.
authors.forename: Patrick Y
authors.initials: PY
authors.lastname: Wen
authors.forename: Larry
authors.initials: L
authors.lastname: Junck
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab